Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Neurotech International Ltd. ( (AU:NTI) ) is now available.
Neurotech International Ltd has achieved significant milestones in its clinical and corporate activities. The European Commission granted Orphan Drug Designation for NTI164, its lead drug candidate for Rett Syndrome, offering potential market exclusivity and regulatory incentives in the EU. Additionally, a Phase I/II clinical trial for NTI164 in Autism Spectrum Disorder showed promising results, supporting its efficacy and safety. The company also signed a development agreement with RH Pharma to enhance its product development capabilities and expand into new markets. Furthermore, Neurotech welcomed Dr. Anthony Filippis as its new Managing Director and CEO, and received a $2.44 million R&D tax incentive refund from the Australian government.
More about Neurotech International Ltd.
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is involved in creating cannabinoid-based therapies, with a market focus on conditions such as Rett Syndrome and Autism Spectrum Disorder.
YTD Price Performance: -50.91%
Average Trading Volume: 678,801
Technical Sentiment Signal: Buy
Current Market Cap: A$28.34M
For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.